Prognostic value of pan-immune-inflammation index in hepatocellular carcinoma compared with albumin-bilirubin and model for end-stage liver disease sodium

Table 3 Univariate Cox regression analysis for overall survival

Variable	HR	95%CI	P value
Age (high vs low)	1.36	0.80-2.33	0.247
Sex (male vs female)	0.67	0.36-1.25	0.205
ECOG performance status (≥ 2 vs 0-1)	3.60	2.05-6.33	< 0.001
BCLC stage (C-D vs A-B)	7.32	3.69-14.52	< 0.001
Cirrhosis (present vs absent)	1.73	1.00-2.99	0.048
Treatment modality (non-curative vs curative)	9.46	3.73-24.00	< 0.001
ALBI grade (2-3 vs 1)	2.66	1.47-4.79	0.001
MELD-Na (high vs low)	2.82	1.62-4.89	< 0.001
PIV (high vs low)	2.83	1.65-4.86	< 0.001
Etiology (viral vs nonviral)	0.85	0.48-1.49	0.573

HR: Hazard ratio; CI: Confidence interval; ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona Clinic Liver Cancer staging system; MELD-Na: Model for end-stage liver disease-sodium; ALBI: Albumin-bilirubin; PIV: Pan-immune-inflammation value.